

## PHARMACY PRE-AUTHORIZATION CRITERIA



<b>DRUG (S)</b>	Duzallo (Ilesinurad/allopurinol) Zurampic (Ilesinurad)
<b>POLICY #</b>	14101
<b>INDICATIONS</b>	<p><b>Zurampic</b> is indicated for the adjunct treatment of hyperuricemia associated with gout (in combination with a xanthine oxidase inhibitor, ie, Allopurinol or Uloric) in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.</p> <p><b>Duzallo</b> is indicated for the treatment of hyperuricemia associated with gout in patients not achieving target serum uric acid levels with allopurinol alone.</p>
<b>CRITERIA</b>	<p>ConnectiCare considers <b>Zurampic and Duzallo</b> to be medically necessary in adults who meet all of the following criteria:</p> <ul style="list-style-type: none"> <li>• Patient has clinically diagnosed hyperuricemia associated with gout</li> <li>• Patient has not achieved a target serum uric acid level using allopurinol (Zyloprim) in a dose of at least 300mg daily (200mg in renal impairment)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Patient has not achieved a target serum uric acid level using febuxostat (Uloric) 80mg daily</li> <li>• Patient has a serum uric acid level above 6mg/dl despite use of Uloric</li> <li>• Patient is not using Zurampic as monotherapy</li> </ul>
<b>LIMITATIONS</b>	Zurampic is not recommended for the treatment of asymptomatic hyperuricemia
<b>REFERENCES</b>	<ol style="list-style-type: none"> <li>1. Duzallo full prescribing information. Ironwood Pharmaceuticals, Inc., Cambridge, MA</li> <li>2. Zurampic full prescribing information. Ironwood Pharmaceuticals, Inc., Cambridge, MA</li> </ol>
<b>P&amp;T REVIEW HISTORY</b>	11/16, 11/17, 1/18, 11/18
<b>REVISION RECORD</b>	11/17, 1/18